Asian OTC markets well-suited for local alliances -- consultant at NDMA annual meeting.
This article was originally published in The Tan Sheet
Executive Summary
STRATEGIC PARTNERSHIPS WITH LOCAL ASIAN OTC COMPANIES should be considered by Western pharmaceutical firms in lieu of acquisitions, Barri Blauvelt, CEO and group president of global management and business development firm Innovara, recommended at the Nonprescription Drug Manufacturers Association annual meeting May 20 in Colorado Springs. Claiming that "few outright acquisitions" of Asian self-medication firms are successful, Blauvelt suggested that alliances allow Western companies to avoid many of the pitfalls associated with the local traits of Asian markets.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning